Table 3. Benefits in survival time judged sufficient to make worthwhile 3 years of sorafenib versus 1 year of sorafenib according to randomly allocated treatment group and time of assessment.

		Time of assessment of patients' preferences												Overall post-baseline
		Baseline		**3 months**			**15 months**			**42 months**				
Treatment group		Sorafenib	Placebo	Sorafenib	Placebo		Sorafenib	Placebo		Sorafenib	Placebo			
N		177	56	129	50		85	40		39	20			
		Median benefit		Median benefit		P-value*	Median benefit		P-value*	Median benefit		P-value*	P-value†	
Baseline	5 years	12m	9m	12m	2m	0.09	9m	6m	0.11	9m	1m	0.30	**0.04**	
prognoses	15 years	12m	11m	12m	2m	0.15	9m	6m	0.13	9m	6m	0.31	0.06	

m, months; * P-values from a mixed model applied to the normal score transformed values with the following covariates fitted: treatment group, baseline value, time point, and a time point by treatment group interaction. † P-value from mixed model as above but without the time point by treatment group interaction (i.e. treatment effect assumed to be constant post-baseline).